As of July 1, 2025, Vaccinex Inc (VCNX) reports a ROE (Return on Equity) of 748.95%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Vaccinex Inc's ROE (Return on Equity)
Over recent years, Vaccinex Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 748.95% |
| 2023-12-31 | 876.29% |
| 2022-12-31 | -381.57% |
| 2021-12-31 | -301.94% |
| 2020-12-31 | 108.56% |
This gradual decrease highlights how Vaccinex Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Vaccinex Inc's ROE (Return on Equity) to Peers
To better understand Vaccinex Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Vaccinex Inc (VCNX) | 748.95% |
| Helix Biopharma Corp (HBP.TO) | 10293.33% |
| Qualigen Therapeutics Inc (QLGN) | 637.83% |
| Yield10 Bioscience Inc (YTEN) | 582.16% |
| Idera Pharmaceuticals Inc (IDRA) | 333.04% |
| Navidea Biopharmaceuticals Inc (NAVB) | 179.86% |
Compared to its competitors, Vaccinex Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.